trivalent cell-based virosomal influenza vaccine

The trivalent cell-based virosomal influenza vaccine is an investigational vaccine candidate developed by Crucell Holland BV (a subsidiary of Janssen/Johnson & Johnson). This vaccine utilizes a cell-culture manufacturing process based on the proprietary PER.C6 human cell line, which offers a more scalable and controlled alternative to traditional egg-based production methods. The vaccine's delivery system employs virosomes—reconstituted influenza virus envelopes that lack genetic material but retain the viral hemagglutinin (HA) and neuraminidase (NA) proteins. These virosomes act as both a delivery vehicle and a physical adjuvant, enhancing the immune response to the antigens. The trivalent formulation is designed to provide protection against three specific strains of the influenza virus, typically including two influenza A subtypes and one influenza B lineage. It was evaluated in Phase 1 clinical trials to assess its safety, tolerability, and immunogenicity in healthy adults.

Other names

trivalent cell-based influenza vaccinecell-based virosomal influenza vaccineCrucell cell-based influenza vaccine